Journey Medical Corp (DERM) Q3 2026 Earnings Call Highlights: Emrosi Momentum Drives Revenue ...
Journey Medical Corp (DERM) posted 8% revenue growth to $19 million and adjusted EBITDA of $3.5 million, fueled by Emrosi demand and a major national formulary win set for 2027. Related Stocks: DERM ,